ArticleJournal of family medicine and primary care2026
Calcitonin-secreting pancreatic neuroendocrine tumor: A case report and literature review.
Article in Journal of family medicine and primary care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Calcitonin-secreting is rare in patients with pancreatic neuroendocrine carcinoma, which is prone to misdiagnosis and needs more attention from clinicians. Here, we present a case of pancreatic head mass with an unexpected high peripheral level of calcitonin and was first misdiagnosed as medullary thyroid carcinoma (MTC). The only significant findings were intermittent defecation, a mass filled with abundant blood supply in the pancreatic uncinate process on contrast-enhanced computerized tomography, and hypercalcitoninemia. Postsurgical pathology confirmed that the mass was a pancreatic neuroendocrine tumor (pNET G2), and preoperatively elevated calcitonin and procalcitonin levels have also decreased to normal. Elevated calcitonin levels are rarely observed in other pathological conditions, such as pancreatic neuroendocrine neoplasms (pNENs), rather than MTC. We report a rare case and review the literature, broadening the phenotypic spectrum of this disease with its unique endocrine manifestations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.